Ian Nisbet and Alan Trounson, AO
Australia is a very challenging environment for early-stage biotechnology companies. Risk capital is hard to find, and investors are wary of over-promising and under-delivering start-ups, that commonly go aground because of limited resources pitched against the costly demands and long timeframes of drug development.
For public companies, there is often a […]
Melbourne, Victoria, Australia – 08 November 2022
The Peter MacCallum Cancer Centre (“Peter Mac”) and Cartherics Pty Ltd (“Cartherics”) announced today they have entered into a Collaborative Development Program Agreement (CDPA) to develop Cartherics’ proprietary autologous CAR-T cell therapy (CTH-001) for the treatment of cutaneous T-cell lymphoma (CTCL).
“Patients with advanced stages of cutaneous T-cell lymphomas often […]
Cartherics is delighted to be participating in Frocktober – Australia’s most fashionable month-long fundraiser to raise awareness and funds for vital ovarian cancer research through the Ovarian Cancer Research Foundation (OCRF).
Ovarian cancer is Australia’s most lethal gynaecological cancer, taking more than 1,000 lives each year. With a five-year survival rate of only 48%, there […]
MELBOURNE, Australia, 13 October 2022 – Cartherics, a biotechnology company developing immune cell therapies for the treatment of cancer, has opened today a brand-new state-of-the-art facility to strengthen the company’s research and manufacturing capabilities, as well as support local innovation. Cartherics invested AU$4M in the newly designed and built facility, which includes PC2 and dedicated […]
Melbourne, Australia, 06 October 2022 – Cartherics, a biotechnology company developing immune cell therapies for the treatment of cancer, announced today that it has been granted US patent 11,400,145, entitled “Genetically modified cells and uses thereof”.
This patent provides a proprietary position for multiple development candidates in Cartherics’ pipeline. Specifically, this patent covers Cartherics’ chimeric […]
MELBOURNE, Australia, 27 September 2022 – Cartherics, a biotechnology company developing immune cell therapies for the treatment of cancer, together within partner institutions, has received $5.4M Medical Research Futures Fund (MRFF) grant to develop a new approach to enhance cancer therapy by engaging the patients’ own immune system to complement CAR cell therapy.
The company, in […]
By Leigh Dayton, 16 June 2022
Cartherics is delighted to announce that Non-Executive Director Bryan Williams is one of the top 1000 scientists worldwide in the field of Genetics and Molecular Biology, according to Research.com, a prominent academic platform for scientists.
In the recently released edition its […]
By Leigh Dayton 9 June 2022
It’s official. As of this month, ovarian cancer campaigner Heather Hawkins takes up her role as an Advisory Board Member for Cartherics.
“It’s a privilege and an honour to be part of the Board,” she says. “And I’m looking forward to assisting […]
Dr Ian Nisbet Chief Operating Officer
Held in partnership with Harvard Stem Cell Institute, this virtual one-day investor and partner conference will explore stem cell therapeutics in the areas of regenerative medicine, oncology and emerging academic research. It will also showcase cutting-edge science, industry trends and the commercial potential of this innovative sector to an invited […]
Alan Trounson is ranked among the world’s most prominent scientists
Cartherics’ mission is the development of novel, immune cell therapy products for the treatment of cancer, endometriosis and Alzheimer’s disease.
Stay informed about our latest news and developments
© Copyright 2022 | Cartherics Pty ltd
